Takahiro Yoneyama

About

Dr. Takahiro Yoneyama is a leading urologic oncologist whose research focuses on the intersection of frailty, geriatric assessment, and surgical outcomes in prostate and bladder cancer. His seminal work on the Geriatric 8 (G8) screening tool has redefined how frailty is evaluated in prostate cancer patients, demonstrating its predictive value for treatment decisions, postoperative pain, and quality of life. With over 40 citations, his 2020 study on G8 screening in prostate cancer remains a cornerstone in geriatric oncology. Dr. Yoneyama is also a pioneer in robotic surgery, having developed the innovative robotic cross-folded U-configuration intracorporeal ileal neobladder for muscle-invasive bladder cancer, a technique that has garnered 31 citations for its impact on functional outcomes. His research portfolio, spanning over 200 citations, consistently shows that frailty—not age alone—is a critical determinant of surgical outcomes, from pain management to oncologic control. Notably, his work on cell-free DNA as a biomarker for surgical damage opens new avenues for minimally invasive surgery evaluation. Dr. Yoneyama’s contributions are shaping personalized, age-aware care in urologic oncology.

Research Focus

Key Achievements

Top Papers

1. 1
   Geriatric 8 screening of frailty in patients with prostate cancer

   40 citations · 2020
2. 2
   Robotic cross-folded U-configuration intracorporeal ileal neobladder for muscle-invasive bladder cancer: Initial experience and functional outcomes

   31 citations · 2018
3. 3
   Effect of frailty and comorbidity on surgical contraindication in patients with localized prostate cancer (FRART-PC Study)

   19 citations · 2020
4. 4
   Frailty is a predictor of moderate to severe pain after robot‐assisted laparoscopic prostatectomy: A case‐control study (FRAP study)

   17 citations · 2020
5. 5
   Minimum incision endoscopic radical prostatectomy: Clinical and oncological outcomes at a single institute

   16 citations · 2011
6. 6
   Oncologic and patient-reported outcomes after robot-assisted radical prostatectomy in men aged ≥75 years

   14 citations · 2021
7. 7
   Utility of total cell-free DNA levels for surgical damage evaluation in patients with urological surgeries

   13 citations · 2021
8. 8
   Neoadjuvant chemohormonal therapy followed by robot-assisted and minimum incision endoscopic radical prostatectomy in patients with high-risk prostate cancer: comparison of perioperative and oncological outcomes at single institution

   13 citations · 2018
9. 9
   The feasibility and effectiveness of robot-assisted radical cystectomy after neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer

   12 citations · 2016
10. 10
    The effect of frailty on the quality of life and lower urinary symptoms following robot-assisted radical prostatectomy: A longitudinal analysis (FRARP-QL Study)

    12 citations · 2020

Key Collaborators

Contact & Links